Pancreatic Cancer

Growth Factor Inhibitor - Gemcitabine Combination Blocks Tumor Growth

Published in Cancer Weekly, September 4th, 2001

by Sonia Nichols, senior medical writer - Pancreatic cancer proliferation and metastasis can be curbed with a new drug combination that blocks epidermal growth factor receptor (EGFR) signaling.

The EGFR protein tyrosine kinase inhibitor (PKI) PKI 166, when given three times a week in combination with intraperitoneal injections of gemcitabine to mice bearing pancreatic tumors, inhibited tumor proliferation and angiogenesis and increased tumor cell apoptosis, researchers at the University of Texas M.D. Anderson Cancer Center in Houston reported. Eventually, the novel therapy could prove useful for treating humans with pancreatic carcinoma, a leading cause of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry